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Abstract




The Graduate School 
Seoul National University
Suppression of tumorigenicity 2 (ST2) which is the receptor of 
IL-33 is involved in renal inflammation and it is also correlated 
with disease severity in chronic kidney disease (CKD). Here, we 
report the ameliorating effect of the ST2 blockade as well as the 
role of ST2 in the progression of renal fibrosis. 
Serum and urine levels of soluble ST2 (sST2) were measured 
in 296 CKD patients. And ST2 mRNA levels were quantified in 
blood and urine cells. Immunohistochemistry (IHC) stain of ST2 
was performed in kidney biopsy samples of CKD patients. 
Further, urine cells were co-stained with 
podocalyxin/aquaporin-1 and ST2 to characterize the cell type. 
And fibrosis induced by TGF-β in primary cultured podocytes 
and proximal tubular epithelial cells (PTECs) were evaluated 
with fibronectin and ST2 mRNA expressions. Anti-ST2 
monoclonal antibody (mAb) was treated to evaluate the 
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neutralizing effect of ST2 on renal fibrosis. Finally, ST2 and 
fibronectin mRNA expression was measured in CKD mouse 
model (UUO; Unilateral Ureteral Obstruction).
 Serum (P = 0.002) and urine (P < 0.001) sST2 levels 
increased as renal function deteriorated. Also, urine ST2 levels 
adjusted by urine creatinine showed the same pattern (P < 
0.001). Serum (P = 0.023) and urine (P = 0.03) ST2 
expressions were elevated in CKD stage 5 patients compared 
with other stages. ST2 IHC staining in CKD stage 5 showed 
3-fold increase than CKD stage 1. When the patients were 
subdivided by 0.5 g/g proteinuria, patients with more proteinuria 
had a higher concentration of urine ST2 (P = 0.02). A large 
portion of urine cells were ST2-rich podocytes/PTECs and the 
proportion of these cells increased as renal function decreased in 
flow-cytometry. After fibrosis induction in primary cultured 
podocytes and PTECs, mRNA and protein expressions of 
fibronectin and ST2 showed positive correlation with the fibrosis 
severity. And anti-ST2 blocking Ab neutralized the fibrosis. In 
UUO mouse model, ST2 and fibronectin expression increased 
over time (P < 0.01).
 Elevated serum and urine ST2 levels are associated with the 
progression of CKD and podocytes/PTECs are involved in this 
process. ST2-mediated signaling may have a considerable role 
in the progression renal dysfunction. And ST2 blockade is a 
potential therapeutic target for renal preservation.
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INTRODUCTION
The prevalence of CKD is gradually increasing worldwide, CKD 
is a major burden to the health care system in terms of not only 
cost, but also co-morbidity and mortality.(1)
Renal fibrosis, characterized by glomerulosclerosis (GS) and 
tubulointerstitial fibrosis (TIF), is a common pathological 
outcome of CKD, regardless of etiology.(2-4) Progressive CKD 
often results in excessive accumulation of extracellular matrix 
that leads to the complete destruction of kidney and end-stage 
renal failure that requires dialysis or kidney transplantation.(5) 
Renal fibrosis represents a failed wound-healing process of the 
kidney tissue after chronic, sustained injury. Among many kinds 
of fibrogenic factors that regulate renal fibrotic process, 
transforming growth factor-β (TGF-β) is one that plays a 
central role. TGF-β can stimulate mesangial cells, interstitial 
fibroblasts, and tubular epithelial cells to undergo myofibroblastic 
activation or transition, to become matrix-producing fibrogenic 
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cells. The hyperfiltration theory of Brenner et al., which 
suggests that the progression of renal disease results from 
glomerular hemodynamic changes, has been emerged as a 
popular concept. However, close pathologic analysis recently 
showed that functional impairment of the kidney is better 
correlated with the degree of tubule-interstitial damage than 
with that of glomerular injury, and this finding in turn has led to 
the broad recognition that the final common pathway of kidney 
failure operates principally in the tubule-interstitium. 
Nevertheless, several reports have shown that podocyte play a 
key role in glomerulosclerosis which results in renal fibrosis by 
interacting with other kidney cells such as mesangial cells, 
endothelial cells and tubular epithelial cells.(6-8)
Suppression of tumorigenicity 2 (ST2) is an interleukin (IL)-1 
receptor family member which exists as soluble (sST2) and 
trans-membrane isoform. Interleukin-33 is the functional ligand 
of ST2 which is known to play an active role in inflammation 
and fibrosis in various organs.(9-11)
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sST2 elevation in kidney diseases has been described in limited 
studies, such as lupus nephritis, renal transplantation and a small 
cohort of CKD patients. Elevated serum sST2 level in Systemic 
lupus erythematosus (SLE) patients was found to correlate with 
disease activity and was sensitive to change, suggesting a 
potential role as a surrogate marker of disease activity.(12) 
Thierry et al. reported that serum and urine IL-33/sST2 levels 
were significantly elevated as soon as 30 min after reperfusion 
during kidney transplantation, showing a potential role of IL-33 
and sST2 as an innate-immune mediator during kidney 
ischemia-reperfusion injury (IRI) in humans.(13)
Elevated concentration of serum sST2 is found in CKD patients 
and correlates with renal functions.(14) Although the serum 
sST2 level has previously been found to be correlated in 
patients with CKD, its causal relationship remains unclear. 
Furthermore, the urine level of sST2 has also not been 
described in CKD patients before.
The role of ST2 has not previously been described in renal 
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fibrosis.(14) On this background, this study aims to examine 
serum and urine levels of sST2 in patients with CKD and to 




Details of patients and controls are summarized in Table 1. We 
recruited Chronic Kidney Disease (CKD) patients who were 
attending the Seoul National University and the Seoul K internal 
medicine clinic. We also recruited healthy subjects. In total, 
samples from 295 CKD patients were included.
Measurement of serum and urine ST2
The sST2 ELISA (catalog no. M3300) kit was obtained from 
R&D Systems, Inc (Minneapolis, MN). ELISA was performed 
according to the manufacturer’s instructions. The lower limit of 
detection for sST2 was 31.3 pg/ml.
Histologic Examination
Paraformaldehyde (4%)-fixed and paraffin-embedded kidneys 
were sectioned at 4 _m and stained with periodic acid-Schiff 
(PAS) by standard methods. All histologic examinations were 
performed by the renal pathologist in a blinded fashion. 
Histopathological changes were individually scored by two 
independent investigators.
Sections were deparaffinized in xylene and rehydrated in a 
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graded series of ethanol. Endogenous peroxidase activity was 
blocked with 0.3% hydrogen peroxidase in methanol for 30 min 
at room temperature. Sections were microwaved for 5 min to 
retrieve the antigen in an antigen unmasking solution. After 
incubation with 5% skim milk for 1 h at room temperature, 
sections were incubated at 4°C with a primary mouse 
monoclonal anti-ST2L antibody and anti-podocalyxin overnight. 
Tissues were washed several times in PBS and incubated for 45 
min with a secondary antibody. Tissues were visualized using a 
DAB or AEC kit, examined under a microscope and 
photographed.
Urine sample collection and RNA extraction
Whole stream early morning urine specimens were collected 
from each study participant, and samples were centrifuged at 
2,000 g for 10 min at 4°C. The urinary supernatant was 
discarded, and the remaining cell pellets were resuspended in 
1.5 ml DEPC-treated PBS and centrifuged at 13,000 g for 5 min 
at 4°C. The pellets were resuspended in 1.0 ml TRIzol Reagent 
(Ambion, Life Technologies) and stored at - 80°C until use. 
Real-time quantitative PCR analysis
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 Total RNA was extracted from podocytes/PTECs and the mRNA 
levels of target genes were assayed by real-time quantitative 
PCR. Briefly, total RNA was isolated from podocytes/PTECs 
using the RNeasy kit (Qiagen GmBH, Germany), and 500 ng of 
total RNA was reverse-transcribed using oligo-d(T) primers 
and AMV-RT Taq polymerase (Promega, WI, USA). Real-time 
qPCR was performed using Assay-on-Demand TaqMan probes 
and primers for NGAL, IL-8, fibronectin, collagen1, αSMA and 
GAPDH (Applied Biosystems, CA, USA) and an ABI PRISM 7500 
sequence detection system. Relative quantification was performed 
using the 2-∆∆CT method. GAPDH was used as a loading control. 
All experiments were completed in triplicate.
 
Western blot analysis
 The podocytes/PTECs were harvested from culture plates and 
proteins were extracted using RIPA buffer containing Halt 
protease inhibitor (Pierce, IL, USA). Western immunoblotting 
was performed using primary antibodies against fibronectin 
(Santa Cruz Biotechnology, Dallas, TX), ST2 (Santa Cruz 
Biotechnology), and β-actin (Sigma-Aldrich). Briefly, equal 
amounts (30 μg) of extracted protein were separated by 10% 
SDS-polyacrylamide gels and transferred onto Immobilon-FL 0.4 
μM polyvinylidene difluoride membranes (Millipore, MA, USA). 
Anti-rabbit IgG (Cell Signaling Technology, MA, USA) and 
anti-mouse IgG (Cell Signaling Technology) were used as 
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HRP-conjugated secondary antibodies. Labeled proteins were 
detected using an enhanced chemiluminescence system (ECLTM 
PRN 2106; Amersham Pharmacia Biotech, Buckinghamshire, UK), 
and the intensities of the bands were analyzed using a gel 
documentation system (Bio-Rad Gel Doc 1000 and 
Multi-Analystversion 1.1).
Confocal microscopic examination
 The microfluidics devices were disassembled for 
immunofluorescence staining, and the cells on the PDMS slabs 
were washed with PBS and fixed in 4% paraformaldehyde for 20 
minutes. Following fixation, the cells were permeabilized with 
0.3% Triton X and stained with antibodies against ST2 (Santa 
Cruz Biotechnology), podycalyxin, and aquaporin-1 in a blocking 
agent overnight at 4°C. Alexa 488/555-conjugated probes 
(Molecular Probes, OR, USA) were used as secondary antibodies 
and 4’,6-diamidino-2-phenylindole (DAPI; Molecular Probes) 
was used to counterstain the nuclei. The primary antibodies 
were omitted in the negative controls. After stimulation, 
Z-sectioned fluorescent images were used to determine the 
localization of podocalyxin/aquaporin-1 in the podocytes/PTECs, 
respectively. Immunofluorescence images were acquired with a 
confocal microscope (Leica TCS SP8, Leica Microsystem GmbH 
Wetzlar, Germany) and were analyzed with Leica IMARIS 7.6. 
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Fluorescence-activated cell sorting (FACS) analysis
FACS analysis was performed using a FACS BD Calibur 
instrument to verify that the ST2 Ab could bind cMet. 
podocytes/PTECs were used. Cells were cultured using F12 
HAMS media supplemented with 10% FBS (Gibco), 1% P/X, 2% 
HEPES and EGM (Lonza, CC-3124). For the experiment, 
podocytes/PTECs cells (5 × 105) were added to a 1.5ml tube, 
and the culture was washed out. Then, 4 l of ST2 Ab was 
diluted in 100 l of PBS, after which this solution was reacted 
with the cell suspension at 4°C for 30 minutes. Afterward, the 
cells were centrifuged at 4000 rpm for 3 minutes and washed 
twice. Then, 2 l of anti-human IgG-PE (Southern Biotech) was 
added to the suspension, and the cells were washed, 
resuspended in 1 ml of PBS, and then subjected to FACS 
analysis.
Podocytes in Culture/Proximal Tubular Epithelial Cells in 
Culture 
 The schematic experimental procedure is presented in Fig. 1. 
Human primary podocytes were harvested as previously 
reported.(15) Surgically resected kidney specimens were 
obtained from patients diagnosed with renal cell carcinoma, and 
the kidney cortices were dissected mechanically. The glomeruli 
were isolated by sieving techniques, and the isolated glomeruli 
were cultured for 8 days. The outgrowing cells were trypsinized 
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and passed through sieves with a 25-m pore size to remove 
the remaining glomerular cores, which primarily consisted of 
mesangial cells.(16) To quantitatively analyze the podocyte from 
the isolated glomeruli, flow cytometry analysis was conducted. 
On day 8, the cultured cells were enumerated, and 1 × 106cells 
were incubated with Fc receptor blocking reagent (1μg/ml, 
BDBioscience, CA, USA). Podocyte were identified using rabbit 
anti-human purified anti-Nephrin (Abcam,Cambridge,UK) and 
FITC-labeled anti-rabbit IgG (BDPharMingen, CA, USA). We 
isolated PTECs from normal adjacent kidney tissue specimens 
from patients with renal cell carcinoma according to guidelines 
approved by the Institutional Review Board of Seoul National 
University Hospital (IRB no. 1404-117-515). After dissecting 
the cortex, the unaffected specimens were minced and digested 
with Hank's balanced salt solution (HBSS) containing 3 mg/mL 
collagenase (Sigma-Aldrich, St. Louis, MO, USA). After 
centrifugation for 5 minutes at 500 g, cortical tubular cells were 
isolated. The cells were then incubated in DMEM/F12. After 4 
hours of incubation, the tubules were collected and cultured on 
collagen-coated petri dishes (BD Biosciences, Franklin Lakes, 
NJ, USA) until colonies of epithelial cells were established, and 
2±3 passages were used in the current study. After 3 days of 
culture, the cells were detached from the dishes with a 3 mM 
EDTA solution and a minimal amount of trypsin. Cells (2 × 
105/well) were seeded on 8-well chamber slides in serum-free 
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medium for 24 hours and then was hed twice with PBS. Next, 
recombinant TGFβ (R&D Systems, Minneapolis, MN, USA) was 
added (final concentration, 10ng/ml) except where indicated.
Fibrosis induction and ST2 blocking Antibody 
Administration 
Renal fibrosis was induced in primary cultured podocytes and 
PTECs with 2ng/ml of recombinant TGF- β. The anti-ST2 
mAb was from Centocor, a pharmaceutical company of Johnson 
& Johnson (CNT03914). Primary cultured podocytes and PTECs 
were treated simultaneously with rTGF-β and 0.25 mcg/ml of 
anti-ST2 mAb. The doses of anti-ST2 mAg were increased to 
0.5 and 1.0 mcg/ml, sequentially.
Annexin V/propidium iodide staining assay
Cell apoptosis and necrosis were measured using an Annexin 
V/propidium iodide (PI) fluorescein isothiocyanate (FITC) 
apoptosis kit (BD, Franklin Lakes, NJ, USA) by flow cytometry 
according to the manufacturer’s instructions.(17-19) Briefly, 
harvested cells (5×105)were washed with cold PBS, 
resuspended in 100μL of binding buffer, stained with 5μL of 
FITC-conjugated Annexin V (10mg/mL) and 10μL of PI 
(50mg/mL), and incubated for 30 minutes at room temperature 
in the dark. Then, the data were acquired and analyzed with 
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BDFACSDivaTM(V8.0, BDBiosciences, Becton, Dickinson and 
Company, CA, USA).
Statistical analysis 
 The results were expressed as the means ± SD or means ± 
SEM where indicated. Statistical analysis was performed using 
GraphPad Prism 5.0 (Graph Pad Software, CA, USA). A P-value 
<0.05 was considered statistically significant.
Ethics statement 
The study protocol complies with the Declaration of Helsinki 
and received full approval from the institutional review board at 
the Seoul National University Hospital (No. H-1701-133-829). 
All the samples were immediately recruited, stored and 
monitored by the SNUH Human Biobank.
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RESULTS
Clinical characteristics of CKD patients
The total number of patients enrolled in this study was 296. The 
baseline characteristics of CKD patients are shown in Table 1. 
The average age was 55.7 years old and 59.5% were male. 
Serum creatinine was 2.28 ± 1.88 and estimated glomerular 
filtration rate (GFR) was 50.2 ± 32.8 which was calculated by 
the Modification of Diet in Renal Disease (MDRD) GFR equation. 
Random urine protein creatinine ratio was 1.34 ± 2.58 g/g.
Serum and urine sST2 in CKD patients 
Serum sST2, measured by enzyme-linked immunosorbent assay 
(ELISA), was significantly increased in patients with CKD stage 
V compared with CKD I, II, III, and IV (P<0.05). And also 
increased in CKD IV compared with CKD I, II, and III (P <0.05). 
Urine sST2 level had a similar pattern with serum sST2, and 
this trend unchanged after sST2 was divided by urine creatinine 
(Figure 1A). These data suggest that sST2 increases 
systemically and locally as kidney function deteriorates 
supporting a key role of ST2 in the progression of renal fibrosis.
Immunohistochemistry for ST2L in kidney specimens of 
CKD patients
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Table 1. Baseline characteristics of CKD pateints.
Data are presented as mean (SEM) or frequencies (percentage). Abbreviations: CKD, chronic kidney disease; 
AST; aspartate transaminase, ALT; alanine transaminase, eGFR, estimated glomerular filtration rate.
CKD stage Total 1 2 3 4 5










































































































































Immunofluorescence and confocal imaging for ST2L in the 
kidney of CKD patients was performed. ST2L was clearly seen 
in glomeruli and also in (proximal) tubular epithelial cells (Figure 
1B, 1C). To determine whether the ST2L staining in the 
glomeruli area was in podocyte, podocalyxin was performed. 
There was an increasing tendency of ST2L staining as kidney 
function deteriorates.
Increased expression of ST2L in whole blood cells and 
urine sediment cells
Increased ST2L mRNA transcripts were measured in whole 
blood cells in CKD 5 patients compared with CKD 2 (P < 0.05), 
3 (P < 0.01), 4 (P < 0.05). IL-8 was also up-regulated in 
whole blood cells in CKD 5 compared with CKD 3 (P < 0.05). 
ST2L mRNA expression was increased in urine sediment cells in 
CKD 5 patients compared with CKD 2, 3, and 4 (P<0.05). But, 
there was no difference in the expression of NGAL mRNA 
(Fugure 1D). Taken together, these data indicated that increased 
expression of ST2L mRNA in whole blood and urine sediment 
cells was consistent with our previous results demonstrating 
overall elevated sST2 levels in serum and urine of CKD patients.
Correlation of serum and urine sST2 and proteinuria in 
CKD patients
When patients were divided into two groups according to 0.5 
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g/g of proteinuria, urine sST2 and urine sST/Cr levels were 
significantly increased in patients with proteinuria more than 0.5 
g/g (P < 0.05). There was no difference in serum sST2 between 
two groups (Figure 1E). As increasing proteinuria is mainly 
related with dysfunction of the podocytes, we hypothesized that 
podocyte might play an important role in the progression of CKD 
and the development of kidney fibrosis.
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Figure 1. ST2 in CKD patients
(A) sST2 concentrations in plasma and urine from CKD patients. 
(B) Representative images of ST2L staning in glomerulus (panel 
1, 2, 3) and tubulo-interstitium (4, 5, 6) from CKD patients. 
Original magnification: X 400. Scale bar 100 um. 
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(C) Representative confocal microscopic images of human kidney 
biopsy samples in CKD 5 patients co-stained for ST2L (red), 
podocalyxin/aquaporin-1 (green) and DAPI (blue). Original 
magnification: X400. 
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(D) Quantitative RT-PCR analyses of the indicated mRNA 
transcript in whole blood cells and urine sediment cells from 
CKD patients. 
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(E) sST2 protein levels in serum and urine of CKD patients 
stratified by proteinuria (0.5g/g). Symbols represent individual 
data points, horizontal bars indicate the mean, and error bars 
indicate SEM (*p < 0.05 , **p < 0.01)
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Anti-ST2 therapy modulates fibrosis in podocytes.
We next further examined which are cellular sources of ST2. 
We thereby performed specific triple immunofluorescence 
staining of urine sediment cells in CKD patients. As kidney 
function deteriorates, there were highly detectable 
ST2-expressing podocytes. The percentage of ST2-expressing 
podocytes increased as the kidney function deteriorates (Figure 
2A) Representative pictures of flow cytometry was showed in 
Figure 2B. Taken together, ST2-expressing kidney cells, 
especially podocytes and PTECs, were increased in kidney and 
urine of patients with reduced kidney function. Therefore we can 
suggest that they might play a key role in the progression of 
CKD represented by renal fibrosis. 
To assess the role of ST2 in kidney cell fibrosis, we 
hypothesized that ST2-mediated pathway would aggravate in 
fibrosis induced kidney cells in vitro experiments. Primary 
cultured human podocytes were treated with TGF-β to induce 
fibrosis. Remarkably, the expression of ST2 mRNA was 
upregulated after TGF-β was introduced (P < 0.05), and 
collagen 1, fibronectin mRNA expression was also increased, 
showing that fibrosis induction was adequately done (Figure 2C). 
We next hypothesized that sST2 blockade would ameliorate 
podocyte fibrosis. Podocytes treat with TGF-β and anti-ST2 
blocking antibody simultaneously displayed significantly down 
regulated expression of fibronectin and collagen 1 compared with 
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TGF-β treated podocytes (P < 0.05). Western-blot analysis of 
podocytes further confirmed these findings by showing 
downregulation of fibronectin after exposure to anti-ST2 mAb 
(Figure 2D).
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Figure 2. Anti-ST2 blockade therapy modulates fibrosis in 
podocytes.
(A) Representative confocal microscopic images of human urine 
samples in CKD 3 and CKD 5 patients co-stained for ST2L 
(green), podocalyxin (red) and DAPI (blue). Original 
magnification: X400 or X1200. 
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(B) Representative flow cytometic analyses of podocalyxin and 
ST2 expression in urine sediment cells of CKD patients.
(C) Quantitative RT-PCR analyses of the indicated mRNA 
transcript in primary cultured podocytes treated with IgG control 
or αST2 Ab after fibrosis induction with rTGF-β1. 
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(D) Western blot analysis of IgG control- or αST2 Ab-treated 
primary cultured podocytes after fibrosis induction with 
rTGF-β1. 
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(E) Flow cytometric analyses of ST2 expression on primary 
cultured podocytes after treating with IgG control, rTGF- β1 
and rIL-33. The combined date represent at least 2 independent 
experiments with similar results. Symbols represent individual 
data points, horizontal bars indicate the mean, and error bars 
indicate SEM (*p < 0.05 , **p < 0.01, ***p<0.001)
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ST2 blockade prevents rTGF-β1-induced apoptosis in 
podocytes
 The role of ST2 in rTGF-β1-induced apoptosis was 
investigated in primary cultured human podocyte followed by 
treatment with or without ST2 blocking Ab (0.5, 1.0 μg/ml). 
Confocal images and flow cytometric analysis both showed that 
ST2 blockade consistantly decreased apoptotic cells in 
dose-dependent manner (Figure 3A, 3B). In confocal images 
WT-1 expression, which is a key regulator of podocyte function 
was restored after treating anti-ST2 Ab, and Bcl-2, which is 
anti-apoptotic regulatory protein also increased after ST2 
blockade (Figure 3C-3E). These data indicate that blocking ST2 
pathway prevented rTGF-β1-induced apoptosis in podocytes.
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Figure 3. Anti-ST2 blockade therapy reduces apoptosis in 
podocytes.
(A) Representative confocal microscopic images for apoptotic 
cells in IgG control- or αST2-treated primary cultured 
podocytes after fibrosis induction with rTGF-β1. Apoptotic cells 
(red), live cells (green). Original magnification: X400. 
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(B) Flow cytometry measurements showed that ST2 blockade 
attenuated rTGF-β1-induced apoptosis. 
- 30 -
(C, D) Percentage of apoptotic cells, WT-1 positive cells and 
BCL-2 positive cells. 
(E) Representative confocal microscopic images of IgG control- 
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or αST2-treated primary cultured podocytes after fibrosis 
induction with rTGF-β1 co-stained for WT-1 (red), BCL-2 
(green) and DAPI (blue). Original magnification: X400. The 
combined date represent at least 2 independent experiments with 
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similar results. Symbols represent individual data points, 
horizontal bars indicate the mean, and error bars indicate SEM 
(*p < 0.05 , **p < 0.01, ***p<0.001)
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Anti-ST2 blockade therapy ameliorates fibrosis in proximal 
tubular epithelial cells.
 As we showed in IHC-stained kidney specimens of CKD 
patients, ST2-expressing PTECs were also increased in the 
urine of CKD III and V patients (Figure 4A). Representative 
pictures of flow cytometry was showed in Figure 4B. To 
demonstrate the effect of ST2 on PTECs fibrosis, we performed 
the same experiment with PTECs. The ST2 was upregulated 
when fibrosis was induced in PTECs compared with control (P < 
0.01). On immunoblot of PTECs, there was also an increase in 
ST2 on TGF-β induced fibrosis compared with control (Figure 
4C). We next determined whether neurtralization of the ST2 
might also protect in PTECs fibrosis induced by TGF-β. In line 
with our previous findings, PTECs treat with an anti-ST2 
blocking antibody displayed significantly down regulated 
expression of collagen 1 and αSMA compared with TGF-β 
treated PTECs (P < 0.05) (Figure 4D).
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Figure 4. Anti-ST2 blockade therapy ameliorates fibrosis in 
proximal tubular epithelial cells.
(A) Representative confocal microscopic images of human urine 
samples in CKD 3 and CKD 5 patients co-stained for ST2L 
(green), aquaporin-1 (red), fibronectin (purple) and DAPI 
(blue). Original magnification: X400 or X1200.
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 (B) Representative flow cytometic analyses of aquaporin-1 and 
ST2 expression in urine sediment cells of CKD patients. 
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(C) Western blot analysis of IgG control- or rTGF-β1- treated 
primary cultured PTECs. 
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(D) Quantitative RT-PCR analyses of the indicated mRNA 
transcript in primary cultured proximal tubular epithelial cells 
(PTECs) treated with IgG control or αST2 after fibrosis 
induction with rTGF-β1. The combined date represent at least 
2 independent experiments with similar results. Symbols 
represent individual data points, horizontal bars indicate the 
mean, and error bars indicate SEM (*p < 0.05 , **p < 0.01, 
***p<0.001)
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ST2 blockade and renal fibrosis in UUO model 
We quantitated body weight (bwt) 14 days after unilateral 
ureteral obstruction (UUO) in mice, bwt decreased after UUO 
and we observed that anti-ST2 mAb treatment prevented the 
decrease of bwt (Figure 5A). And we quantitated kidney fibrosis 
by Masson’s trichrome staining. Two weeks after UUO, renal 
fibrosis was extensive; however, antiST2-treated UUO mice 
exhibited reduced renal fibrosis (Figure 5B). To further test the 
notion that the administration of anti-ST2 mAb would reduce the 
development of kidney fibrosis, we performed RT-PCR and 
confocal image analyses. And ST2, fibronectin was decreased 
after anti-ST2 treatment. (Figure 5C, 5D). In western blot 
assay, IL-33, Snail, aSMA, b-galactosidase and Bax increased 
after UUO and this observation prevented as anti-ST2 mAb was 
treated (Figure 5E, 5F).
Collectively we provided experimental evidence that ST2 
contributes to the progression of renal fibrosis in two 
experimental in vitro models of kidney cell fibrosis, suggesting 
that pharmacological inhibition of ST2 might represent a novel 
therapeutic role in renal fibrosis.
- 39 -
Figure 5. ST2 blockade and renal fibrosis in UUO model 
(A) Body weight of IgG control- or αST2-treated mice at day 
14 after UUO. 
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(B) Representative images of kidney sections stained for Sirius 
red and histologic quantification of percentage of Sirius red 
positive area over total area in IgG control- or αST2-treated 
mice at day 14 after UUO. 




Representative confocal microscopic images (D) and Western 
blot analysis (E, F) in IgG control- or αST2-treated mice after 
UUO. UUO, Unilateral-Ureteral Obstruction. The combined date 
represent at least 2 independent experiments with similar 
results. Symbols represent individual data points, horizontal bars 




This is the first study, to our knowledge, to demonstrate that 
elevated serum and urine level of sST2 in CKD patients is in 
correlation with renal function. More importantly, we report that 
podocytes and PTECs are involved in ST2-related renal fibrosis 
and inhibition with anti-ST2 mAb ameliorated the progression of 
fibrosis. 
ST2, an IL-1 receptor family member, has known to play a 
key role in tissue fibrosis in various studies. For example, it has 
recently been shown that ST2 promotes the initiation and 
progression of pulmonary fibrosis by recruiting 
ST2+macrophages and ST2+innate lymphoid cells in mice(17). 
IL-33/ST2 has also been shown to activate hepatic stellate cell 
via IL-13 which results in pathologic tissue remodeling and 
hepatic fibrosis(18). A recent study showed that IL-33/ST2 
pathway had a cardioprotective fibroblast-cardiomyocyte 
paracrine system which is mechanically activated(19). 
Renal fibrosis is characterized by glomerulosclerosis and 
tubulointerstitial fibrosis. Podycytes are recognized to play a key 
role in the development of kidney fibrosis, especially 
glomerulosclerosis. Previous studies showed podocytes are 
involved in mesangial cell and endothelial cell survival and 
differentiation via vascular endothelial growth factor A 
(VEGF-A), which is produced by podocytes. Selective loss of 
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overproduction of VEGF by podocytes results in endothelial cell 
and mesangial cell dysfunction and progressive 
glomerulosclerosis (6, 7, 20). Moreover, recent data 
demonstrated podocyte-induced epithelial-mesenchymal 
transition (EMT) which is induced by TGF-β1, also contributes 
to the development of kidney fibrosis(8). The observation that 
podocytes undergo EMT suggests an incredible plasticity of 
these terminally differentiated cells in certain pathological 
conditions. Given that podocyte and tubular epithelial cells are 
developmentally derived from the same origin, it comes as little 
surprise that podocytes, similar to tubular epithelial cells, 
undergo a phenotypic conversion after TGF-β1 stimulation(8).
On the other hand, tubular EMT is a, well known, pathogenic 
mechanism that occurs in the fibrotic tissue after recurrent 
chronic injury which results in tubulointerstitial fibrosis(21, 22).
 It is widely accepted that transforming growth factor-b 
(TGF-β) and its downstream Smad signaling play an essential 
role. The importance of TGF-β in tissue fibrosis in general, and 
renal fibrosis in particular.
Upregulation of TGF-β is a universal finding in virtually every 
type of CKD, both in animal models and in humans. In vitro, 
TGF-β as a sole factor can stimulate mesangial cells, interstitial 
fibroblasts, and tubular epithelial cells to undergo myofibroblastic 
activation or transition, to become matrix-producing fibrogenic 
cells. 
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In the present study, ST2 expression was increased after 
TGF-β induction in both primary cultured podocytes and 
PTECs. Furthermore, after ST2 blockade, fibrosis was 
neutralized in both podocytes and PTECs. Collectively we 
propose that ST2 is involved in renal fibrosis in both podocytes 
and PTECs. And the findings reported here strongly suggest a 
mechanism of both glomerulosclerosis and tubulointerstitial 
fibrosis. During this mechanism ST2 might play a key role to 
these two types of kidney cells.
Inflammation and fibrosis often occur simultaneously in CKD, 
suggesting that both are associated with disease progression 
(23,24). However, molecular mechanisms linking these activities 
have not been fully clarified. Many reports indicate that TGF-β 
plays a pivotal role in the development of fibrosis, and also 
SNAIL, which is a transcriptional factor, is a potent inducer of 
renal fibrosis (25). Recent reports suggest that renal fibrosis, 
especially tubular epithelial cells might be regulated by signaling 
upstream of SNAIL (26). We demonstrated in UUO model that 
SNAIL expression was increased after fibrosis induction, and 
ST2 blockade prevented not only the expression of SNAIL, but 
also the protein expressions of fibrosis markers such as αSMA. 
It is well known that excessive apoptosis promotes fibrosis and 
organ dysfunction (27,28), and there are evidence for an 
apparent interplay between early apoptosis and subsequent 
fibrosis, and the apoptosis could be an early event that occurs 
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before the onset of fibrosis (29-31). We showed that in primary 
cultured human podocytes, exposure to anti-ST2 Ab prevented 
TGF-β induced apoptosis and fibrosis, respectively. In UUO 
mouse model, ST2 blockade significantly attenuated the protein 
expression of Bax and αSMA, simultaneously. Taken together, 
our data indicate that ST2 blockade ameliorates renal fibrosis by 
inhibiting both renal podocyte apoptosis and TIF.
In this study, we evaluated serum and urine sST2 levels in 
CKD patients and found that increased levels of sST2 is related 
with the process of renal fibrosis. However, there was no data 
with in vivo animal CKD models. Further investigation are 
required to figure out the mechanisms and the exact effects in 
renal fibrosis.
Kidney is composed of various kinds of cells such as vascular 
endothelial cells, mesangial cells, podocytes, tubular cells, 
fibroblasts and stromal cells. Renal fibrosis is a complex 
histopathological process which clearly necessitates the 
participation and interaction of many types of kidney resident 
and infiltrated cells (32,33). Therefore, further studies to 
explore the role of other renal cells and the interactions between 
these cells in ST2-mediated renal fibrosis.
 In summary, our findings demonstrated podocytes and PTECs is 
considerably related in ST2-mediated renal fibrosis that can be 
blocked with anti-ST2 mAb. And we suggest that ST2 blockage 
offers new perspectives on a novel therapeutic target to prevent 
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and treat renal fibrosis in CKD patients.
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IL-33의 수용체인 Suppression of tumorigenicity 2 (ST2)는 신손상
이 발생하였을 때 신조직을 보호하고 재생하는데 중요한 역할을 하는 것
으로 알려져 있다. 본 연구에서는 신장섬유화 과정에서 ST2를 차단하는 
것이 신장섬유화에 미치는 영향 및 기전에 대해 보고하고자 한다. 
본 연구에서는 296명의 만성콩팥병 환자에서 혈청 및 소변의 sST2 농
도를 측정하였다. 말초혈액 및 소변에서 ST2 mRNA 농도를 측정하였
고, 면역형광염색을 통해 만성콩팥병 신장 환자들에서 ST2의 존재여부
를 확인하였다. 소변세포를 분리하여 podocalyxin/aquaporin-1 및 
ST2를 동시에 염색하여 이러한 소변 세포의 종류를 확인하였다. 초대배
양한 인체 족세포 및 근위세뇨관세포에서 TGF-β를 통해 섬유화를 유
도하였고, 이후에 ST2 monoclonal Ab를 처리하여 신장섬유화가 호전
되는지를 평가하였다. 마지막으로 만성콩팥병 동물모델(UUO)에서 ST2 
및 섬유화 표지자를 확인하고, ST2 Ab를 처리하였을 때 섬유화 호전여
부를 평가하였다. 
sST2 농도는 만성콩팥병 환자의 신기능이 감소함애 따라 혈청 
(P=0.023)과 소변(P<0.001)에서 감소하였다. 단백뇨 0.5g/g을 기준으
로 나누었을 때 단백뇨가 많은 환자들에서 소변 sST2 농도가 통계적으
로 높은 것을 확인하였다 (P=0.02). 만성콩팥병 환자들의 소변에서 신
기능이 감소함에 따라 ST2가 발현된 신장 족세포 및 근위 세뇨관 세포
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의 비율은 증가하였다. 신장 족세포 및 근위 세뇨관 세포에 섬유화를 유
발시키면 ST2 발현이 증가하는 것을 확인하였고, ST2 차단 항체를 처
리하였을 때 이러한 섬유화는 호전되었다. UUO 만성콩팥병 동물모델에
서 ST2 차단 항체를 투여하였을 때 fibronectin 등의 섬유화 표지자가 
감소하는 것을 확인하였다 (P<0.01).
만성 콩팥병이 진행함에따라 혈청 및 소변 sST2의 농도는 증가하고, 이
러한 과정에는 신장 족세포 및 근위세뇨관 세포가 관여한다. ST2매개 
신호체계는 신장섬유화 과정에 상당한 역할을 할 것으로 예상되고, ST2 
차단 항체는 신장기능을 보호하는 중요한 치료제가 될 수 있겠다. 
주요어: ST2, 신장 족세포, 근위 세뇨관 세포, 만성 콩팥병, 신장 섬유
화.
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